Drug delivery system for treatment of cancer

Abstract

Described herein is a hydrophobic anti-cancer drug encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.

1 . A method for treatment of cancer in a subject, the method comprising intracavitary administering to the subject a poly (alkyl cyanoacrylate) nanoparticle, the nanoparticle comprising a hydrophobic anti-cancer drug, and wherein the nanoparticle is administered to the subject in an amount sufficient to treat the cancer in the subject. 
     
     
         2 . The method of  claim 1 , wherein the intracavitary administration is an intraperitoneal administration. 
     
     
         3 . The method of  claim 1 , wherein the nanoparticle is administered in an amount sufficient to inhibit metastasis of the cancer in the subject and the method comprises inhibiting metastasis in the subject. 
     
     
         4 . The method of  claim 1 , wherein the nanoparticle is produced according to a miniemulsion anionic polymerization process. 
     
     
         5 . The method of  claim 4 , wherein the hydrophobic anti-cancer drug is encapsulated by the nanoparticle. 
     
     
         6 . The method of  claim 4 , wherein the nanoparticle has dimensions below 800 nm. 
     
     
         7 . The method of  claim 4 , wherein the nanoparticle has an average dimension from 80 nm to 200 nm. 
     
     
         8 . The method of  claim 4 , wherein the nanoparticle is PEGylated. 
     
     
         9 . The method of  claim 4 , wherein the alkyl chain of the cyanoacrylate is selected from the group consisting of n-butyl- (BCA), 2-ethyl butyl (EBCA), polyisohexyl (IHCA) and octyl cyanoacrylate (OCA). 
     
     
         10 . The method of  claim 5 , wherein the hydrophobic anti-cancer drug comprises 1-90 wt % of the total weight of the nanoparticle. 
     
     
         11 . The method of  claim 5 , wherein the hydrophobic anti-cancer drug is a taxane. 
     
     
         12 . The method of  claim 11 , wherein the taxane is cabazitaxel. 
     
     
         13 . The method of  claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, peritoneal cancer, colorectal carcinoma, gastric cancer, rectal carcinoma glioma, lung cancer, renal cancer, liver cancer, spleen cancer, gallbladder carcinoma, lymphoma, adrenocortical carcinoma, testicular cancer, urothelium transitional cell carcinoma, and ovarian cancer. 
     
     
         14 . The method of  claim 2 , wherein the cancer is primary peritoneal cancer, peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, gastric cancer, renal cancer, rectal carcinoma, pseudomyxoma peritonei, pancreatic carcinoma, hepatocellular carcinoma, gallbladder carcinoma, appendiceal malignancies, endometrial carcinoma, cervical cancers, breast cancer, lung cancer, malignant melanoma, adrenocortical carcinoma, or transitional cell carcinoma of the urinary tract. 
     
     
         15 . The method of  claim 1 , wherein the subject is a mammalian subject. 
     
     
         16 . The method of  claim 15 , wherein the subject is a human subject.